Search the Newsreel

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and …

Novo Nordisk (CPSE:NOVO B) Launches Kyinsu In China Through Fangzhou Internet Hospital

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novo Nordisk (CPSE:NOVO B) and Fangzhou have launched Kyinsu®, the world's first once weekly basal insulin/GLP-1 RA combination therapy, in China. The product is being introduced through …

Does EU Approval of Wegovy Pill Change NVO's Competitive Story?

Novo Nordisk NVO received a meaningful commercial boost last week after the European Commission approved the oral version of Wegovy (semaglutide 25 mg) for adults with obesity and at least one weight-related comorbidity. The approval expands the company's obesity franchise across Europe, making Wegovy …

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

July 2026 CHMP meeting commences today, prior to FDA inspection classification for Catalent Indiana LLC (part of Novo Nordisk) fill-finish facility Apitegromab CHMP Opinion expected following resolution of Catalent Indiana classification status or inclusion of second fill-finish facility in MAA CAMBRIDGE, Mass., July 20, …

Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

Fangzhou Inc. SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its Internet hospital platform, …

Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The European Commission approved Novo Nordisk A/S' Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity or overweight with at least one weight-related …

Novo Nordisk hebt Prognose leicht an

Novo-Nordisk-Aktie vor den Zahlen: So gut war die Ausgangslage lange nicht!

Novo Nordisk Aktie Prognose: Gewinnwarnung und Aktienrückkauf

Novo Nordisk Aktie Prognose: 2,1 Mrd. $ Vivtex-Deal

Buy or Goodbye?: Nestle, Bayer, Novo Nordisk und Ryanair - Die Analystenstimmen des Tages

Novo Nordisk A/S: Finanzdaten Prognosen Schätzungen und Erwartungen | A3EU6F | DK0062498333